A peptide that is stable for only days in solution can remain stable for months to years as a dry powder under proper storage (GenScript)
doi: 10.12968/bjcn.2016.21.Sup12.S16
The transduced HEK293 cells were subject to selection with puromycin (2 g/ml) (Thermo Fisher, J67236.XF), to select for cells that were stably transduced to express human ACE2

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI